Similar associations between the proportion of RAS (KRAS, NRAS) or BRAF mutations in mutant PIK3CA and wtPIK3CA, although not always statistically significant, were found in disease-specific subanalysis in colorectal cancer (14/18 [78%] vs. 42/86 [49%]; p = 0.04), ovarian cancer (5/7 [71%] vs. 2/43 [5%]; p<0.001), and all tested cancers excluding colorectal (10/33 [30%] vs. 52/299 [17%]; p = 0.1) (Figure 3B–D).We also analyzed the frequency of PIK3CA mutations in patients with mutant RAS (KRAS, NRAS) or BRAF compared to patients without RAS (KRAS, NRAS) or BRAF mutations. This evidence concerns the gene KRAS and ovarian cancer.